HBOT for Long COVID Recovery: What the Research Shows

Quick Answer

Hyperbaric oxygen therapy (HBOT) is being studied as a treatment for Long COVID, with the most promising clinical trial — a 2021 Israeli randomized controlled trial — showing measurable cognitive and fatigue improvements after 40 sessions at 2.0 ATA of near-100% oxygen. This is clinical-pressure HBOT, delivered in a medical facility under physician supervision. Mild hyperbaric chambers (1.1–1.7 atm), like the ones used for home wellness, have not been studied at the same scale for Long COVID and should be understood as general recovery support — not a substitute for clinical treatment.

—

Long COVID Is Not a Small Problem

An estimated 5–30% of people infected with COVID-19 report symptoms lasting three months or longer — fatigue, “brain fog,” shortness of breath, and exercise intolerance are the most common. For a condition this widespread, patients are — understandably — searching for anything that helps. HBOT is one of the few interventions with actual randomized trial data behind it, which is why it keeps coming up in Long COVID forums and physician recommendations alike.

But “HBOT” is not one single thing. The pressure, oxygen concentration, and clinical supervision involved all change what the therapy can realistically do — and that distinction matters enormously for anyone researching options.

What the Research Actually Shows

The strongest data point comes from a randomized, sham-controlled trial published by Zilberman-Itskovich et al. (2022, Scientific Reports), which is the study most Long COVID researchers cite:

Study Detail	Specification
Design	Randomized, double-blind, sham-controlled trial
Protocol	40 sessions, 5x/week, 90 minutes each
Pressure	2.0 ATA
Oxygen	Near-100% medical-grade
Outcome measured	Cognitive function, fatigue, sleep, pain
Result	Significant improvement in global cognitive score, attention, and executive function vs. sham group

The mechanism proposed is consistent with what’s known about HBOT’s biological effects at clinical pressure: increased plasma oxygen delivery to under-perfused brain tissue, reduced neuroinflammation, and stimulation of neuroplasticity through the hyperoxic-hypoxic paradox — the same cellular signaling pathway (HIF-1α activation) involved in stem cell mobilization and angiogenesis. We’ve written a full technical breakdown of this mechanism here if you want to understand the biology in more depth.

The Critical Distinction: Clinical HBOT vs. Mild HBOT

This is where most Long COVID content online gets misleading. The 2.0 ATA protocol used in published trials is clinical hyperbaric oxygen therapy — delivered in hard-shell chambers at hospitals or accredited clinics, with near-100% oxygen and full medical supervision.

Factor	Clinical HBOT (Trial Protocol)	Mild HBOT (Home/Wellness)
Pressure	2.0 ATA	1.1–1.7 atm
Oxygen source	Near-100% medical-grade	Ambient air, oxygen-enriched
Setting	Hospital / accredited clinic	Home, spa, wellness center
Supervision	Physician-supervised	Self-administered
Regulatory status for Long COVID	Investigational, studied in RCTs	Not studied at this scale; general wellness use
Realistic use case	Structured medical treatment	Recovery support, relaxation, daily wellness routine

If you’re specifically pursuing HBOT to treat diagnosed Long COVID symptoms, this is a conversation to have with a physician about accessing a clinical program — not a decision to make around a home wellness chamber alone.

What Mild HBOT Can Reasonably Offer

Where mild hyperbaric chambers do have a legitimate role is in general wellness and recovery support — the category they’re actually built and marketed for. Many Long COVID patients report ongoing fatigue and reduced exercise tolerance long after the acute infection resolves, and oxygen-enriched rest sessions are commonly used by this population as part of a broader recovery routine alongside sleep hygiene, graded exercise, and physician-guided care.

The AURA One, our single-person home chamber, is designed for exactly this kind of daily wellness use — quiet operation, simple touchscreen controls, and adjustable pressure up to 1.7 atm for those building a sustained recovery routine at home. For clinics or rehabilitation centers that want to offer a supervised recovery environment for two people at once, the TITAN Duo is built for that higher-frequency, dual-occupancy use case.

Neither product is a clinical treatment for Long COVID, and neither should be marketed or used as one. They are wellness tools that some patients use as part of a broader recovery plan under their doctor’s guidance.

FAQ

No therapy currently “cures” Long COVID, including clinical HBOT. The published research shows measurable improvement in specific symptoms (cognition, fatigue) using a 2.0 ATA clinical protocol — not a cure, and not yet replicated at the pressure levels used in mild/home chambers.

The published Long COVID trials used 2.0 ATA — higher than the maximum pressure of most mild hyperbaric chambers. There is no published data confirming that 1.7 atm produces equivalent cognitive or fatigue outcomes. Mild chambers should be considered a different category of use, not a lower-dose version of the same treatment.

Yes. This is true for both clinical and mild HBOT. A physician can help you understand whether your specific symptoms are appropriate for hyperbaric intervention and can refer you to an accredited clinical program if warranted.

Ongoing and completed trials are listed on ClinicalTrials.gov under “hyperbaric oxygen” and “post-COVID condition.” Discuss enrollment eligibility with your treating physician.

—

This article is for educational purposes only and is not medical advice. Hyperbaric oxygen therapy for Long COVID at clinical pressures (2.0 ATA+) should only be pursued under physician supervision at an accredited facility. HyperbaricO2Care manufactures mild hyperbaric chambers (1.1–1.7 atm) intended for general wellness use and does not market its equipment as a treatment for Long COVID or any diagnosed medical condition. Reference: Zilberman-Itskovich et al., “Hyperbaric oxygen therapy improves neurocognitive functions of post-COVID-19 condition,” Scientific Reports, 2022.